Table 3.
Vaccination characteristics among 43 099 pregnant individuals who received one dose or more of a covid-19 vaccine during pregnancy. Values are numbers (percentages) unless stated otherwise
| Characteristics | ≥1 vaccine dose during pregnancy (n=43 099) |
|---|---|
| No of doses received during pregnancy | |
| One dose | 13 416 (31.1) |
| Two doses | 29 650 (68.8) |
| Three doses | 33 (0.1) |
| No of doses received during and/or after pregnancy | |
| One dose during pregnancy | 422 (1.0) |
| One dose during, one dose after, pregnancy | 5555 (12.9) |
| One dose during, two doses after, pregnancy | 7439 (17.3) |
| Two doses during pregnancy | 9646 (22.4) |
| Two doses during, one dose after, pregnancy | 20 004 (46.4) |
| Three doses during pregnancy | 33 (0.1) |
| Trimester of vaccine dose 1 (overall) | |
| First | 5213 (12.1) |
| Second | 20 715 (48.1) |
| Third | 17 171 (39.8) |
| Median (IQR) gestational age (days) | 176 (126-222) |
| Median (IQR) gestational age (weeks) | 25.1 (18.0-31.7) |
| Trimester of vaccine dose 1 (only one dose during pregnancy; n=13 416): | |
| First | 93 (0.7) |
| Second | 1409 (10.5) |
| Third | 11 914 (88.8) |
| Median (IQR) gestational age (days) | 237 (217-253) |
| Median (IQR) gestational age (weeks) | 33.9 (31.0-36.1) |
| Trimester of vaccine dose 1 (only two doses during pregnancy; (n=29 650): | |
| First | 5091 (17.2) |
| Second | 19 302 (65.1) |
| Third | 5257 (17.7) |
| Median (IQR) gestational age (days) | 147 (110-184) |
| Median (IQR) gestational age (weeks) | 21.1 (15.7-26.3) |
| Trimester of vaccine dose 2 (only two doses during pregnancy; n=29 650) | |
| First | 301 (1.0) |
| Second | 13 019 (43.9) |
| Third | 16 330 (55.1) |
| Median (IQR) gestational age (days) | 204 (165-239) |
| Median (IQR) gestational age (weeks) | 29.1 (23.6-34.1) |
| Vaccine product received for dose 1 | |
| BNT162b2 (Pfizer-BioNTech) | 34 526 (80.1) |
| mRNA-1273 (Moderna) | 8453 (19.6) |
| Other* | 120 (0.3) |
| Vaccine product for those who received two doses of mRNA vaccine during pregnancy (n=29 574) | |
| BNT162b2+BNT162b2† | 19 866 (67.2) |
| mRNA-1273+mRNA-1273† | 5321 (18.0) |
| BNT162b2+mRNA-1273 or mRNA-1273+BNT162b2‡ | 4387 (14.8) |
IQR=interquartile range.
*
Includes non-mRNA covid-19 vaccines (eg, manufactured by Oxford-AstraZeneca and Johnson & Johnson-Janssen).
†
Same type of mRNA vaccine for doses 1 and 2 (homologous mRNA series).
‡
Different type of mRNA vaccine for doses 1 and 2 (heterologous mRNA series).